1.40
+0.01(+0.72%)
Currency In USD
Address
2445 Technology Forest Boulevard
The Woodlands, TX 77381
United States of America
Phone
281 863 3000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
103
First IPO Date
April 07, 2000
| Name | Title | Pay | Year Born |
| Dr. Michael S. Exton Ph.D. | Chief Executive Officer & Director | 830,545 | 1970 |
| Ms. Kristen L. Alexander | Vice President of Finance & Accounting | 379,807 | 1968 |
| Dr. Alan J. Main Ph.D. | Executive Vice President of Innovation & Chemical Sciences | 595,452 | 1954 |
| Mr. Brian T. Crum | Senior Vice President, General Counsel & Secretary | 616,116 | 1973 |
| Dr. Craig B. Granowitz M.D., Ph.D. | Senior Vice President & Chief Medical Officer | 717,078 | 1965 |
| Mr. Dixon Terry | Vice President of Compliance | 0 | N/A |
| Ms. Desiree Gendron | Vice President of Sales & Training | 0 | N/A |
| Ms. Carrie Siragusa | Vice President of Marketing | 0 | N/A |
| Mr. Scott M. Coiante | Senior Vice President & Chief Financial Officer | 0 | 1967 |
| Ms. Lisa M. DeFrancesco | Senior Vice President of Investor Relations & Corporate Communications | 0 | 1980 |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.